Gilead Sciences share price logo

Gilead Sciences

NASDAQ: GILD

$145.65

-0.99

(-0.68%)

as on

Gilead Sciences Stock Performance

as on September 10, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $145.00
    $147.68
    downward going graph

    0.45%

    Downside

    1.39%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $108.46
    $157.29
    downward going graph

    25.53%

    Downside

    7.99%

    Upside

    downward going graph

Gilead Sciences share price movements today

Previous Close
$146.64
Open
$145.46
Volume
2.4M
Market Cap
$187.2B
Dividend Yield
219.59%
Day's Low - High
$145.00 - $147.68
52 Week Low - High
$108.46 - $157.29

Gilead Sciences Historical Returns

1 Month Return
+ 10.08 %
3 Month Return
+ 16.84 %
1 Year Return
+ 26.68 %
3 Year Return
+ 92.95 %
5 Year Return
+ 107.68 %

Gilead Sciences Stock Fundamentals & Key Indicators

Check Gilead Sciences market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$187.2B

EPS (TTM)

-0.4306

Dividend Yield

219.59%

Quarterly Earnings Growth YOY

0.55%

PE Ratio (TTM)

0

PEG Ratio

2.0262

EBITDA

14.6B

Revenue (TTM)

30.5B

Profit Margin

-10.64%

Return On Equity TTM

-20.68%

Gilead Sciences vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Gilead Sciences with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
HOLD$187.2B107.68%NA-10.64%219.59%
BUY$1.1T368.3%37.6584.01%0.6%
BUY$663.3B60.12%31.1170.45%1.96%
BUY$453.2B131.92%70.6871.48%2.7199999999999998%
BUY$370.9B101.11%120.264.77%226.32%

Stock Returns calculator for Gilead Sciences Stock including INR - Dollar returns

The Gilead Sciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Gilead Sciences investment value today

Current value as on today

₹1,35,597

Returns

₹35,597

(+35.6%)

Returns from Gilead Sciences Stock

₹25,821 (+25.82%)

Dollar Impact

₹9,776 (+9.78%)

Analyst Recommendation on Gilead Sciences Stock

Based on 21 analysts

HOLD

80.95%

Buy

19.05%

Hold

0.00%

Sell

Based on 21 analysts, 80.95238095238095% of analysts recommend a 'HOLD' rating for Gilead Sciences. Average target price of $157.41

Gilead Sciences Share Price Target

Get share price movements and forecasts by analysts on Gilead Sciences.

What analysts predicted

7.47%UPSIDE

Target Price

$157.41

Current Price

$145.65

Analyzed by

21 Analysts

Target

$157.41

Gilead Sciences target price $157.41, a slight upside of 7.47% compared to current price of $145.65. According to 21 analysts rating.

Gilead Sciences Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
6,686
6,953
7,545
7,569
6,667
7,081
7,769
7,924
6,960
7,803
Gross Profit
5,134
5,409
5,971
5,988
5,127
5,580
6,200
6,300
5,515
6,224
Operating Income
-4,322
2,644
888
2,452
2,237
2,474
3,327
2,988
2,692
-10,394
EBITDA
-3,542
2,984
1,884
3,109
2,605
3,374
4,583
3,020
3,509
-10,007
Interest Expense
254
237
238
249
260
254
256
255
240
247
Depreciation
690
694
690
693
696
691
686
687
689
698
Income Before Tax
-4,486
2,053
956
2,167
1,649
2,429
3,641
2,078
2,580
-10,254
Income Tax Expense
-315
438
-297
385
334
468
589
-105
559
242
Net Income
-4,170
1,614
1,253
1,783
1,315
1,960
3,052
2,183
2,021
-10,496
Net Profit Margin
-62.37%
23.21%
16.61%
23.56%
19.72%
27.68%
39.28%
27.55%
29.04%
-134.51%

Gilead Sciences Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
30,390
26,107
22,127
22,449
24,689
27,305
27,281
27,116
28,754
29,442
Gross Profit
26,129
21,736
17,274
17,774
20,117
20,704
21,624
27,116
22,503
23,208
Operating Income
17,633
14,124
8,200
4,287
4,071
9,918
7,330
7,605
1,662
11,701
EBITDA
19,219
15,933
10,305
7,559
4,133
11,329
8,852
7,605
4,434
13,580
Interest Expense
964
1,118
1,077
995
984
1,001
935
944
977
1,024
Depreciation
-
1,286
1,429
1,404
1,480
2,050
2,103
2,533
2,767
2,760
Income Before Tax
17,097
13,529
7,799
5,160
1,669
8,278
5,814
6,859
690
9,796
Income Tax Expense
3,609
8,885
2,339
-204
1,580
2,077
1,248
-1,247
211
1,286
Net Income
13,501
4,628
5,455
5,386
123
6,225
4,592
5,665
480
8,510
Net Profit Margin
44.43%
17.73%
24.65%
23.99%
0.50%
22.80%
16.83%
20.89%
1.67%
28.90%

Gilead Sciences Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
1,614
1,253
1,783
1,315
1,960
3,052
2,183
2,021
-2,021
Operating Cash Flow
1,325
4,309
2,975
1,757
827
4,108
3,327
2,544
3,573
Investing Cash Flow
-307
-710
-225
-415
-2,116
-427
-1,835
1,770
-10,347
Financing Cash Flow
-2,953
-1,379
2,260
-3,426
-1,567
-1,489
-1,263
-4,239
2,344
Change in Cash
-1,946
2,265
4,954
-2,065
-2,782
2,186
234
64
-4,449

Gilead Sciences Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
4,644
5,460
5,364
89
6,201
4,566
5,665
480
8,510
Operating Cash Flow
11,898
8,400
9,144
8,168
11,384
9,072
8,006
10,828
10,019
Investing Cash Flow
-16,069
14,355
-7,817
-14,615
-3,131
-2,466
-2,265
-3,449
-4,793
Financing Cash Flow
3,393
-12,318
-7,634
770
-8,877
-6,469
-5,125
-3,433
-7,745
Change in Cash
-641
10,352
-6,309
-5,634
-659
74
673
3,906
-2,427

Mutual Funds that own Gilead Sciences Stock

Check out the Mutual Funds with significant holdings in Gilead Sciences.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
6.766073%
83896282
Fidelity Concord Street Trust
1.764301%
21876551
Dodge & Cox Funds
1.555402%
19286292
Income Fund of America
1.249928%
15498550
Fidelity Contrafund
1.194988%
14817325

Global Institutional Holdings in Gilead Sciences

Funds
Holdings
Vanguard
8.95%
iShares
6.23%
SPDR
4.06%
Invesco
4.03%
John A. Gunn
1.91%

Gilead Sciences News & Key Events

  • img

    Today's Timeline - 08 September

    Tue, 10:30 PM

    -

    Gilead opens a new 182,000-square-foot Research Center in Foster City, part of a $32 billion investment program.

    Wed, 01:35 AM

    -

    Assembly Biosciences shares 40% of development costs for HSV program with Gilead Sciences under collaboration agreement.

Insights on Gilead Sciences

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Gilead Sciences, Inc. has shown positive revenue growth over the last two quarters. Revenue increased from $6.95 billion to $7.80 billion, reflecting an average increase of 10.8% per quarter.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, GILD has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, GILD stock has moved up by 9.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Merck & Co., Inc. has given 75.6% return, outperforming this stock by 49.2%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Gilead Sciences, Inc. has experienced a decline in net profit for the last four quarters. The profit has decreased from $3.05 billion to -$10.49 billion, indicating an average decrease of 218.4% each quarter. This consistent downward trend highlights significant financial challenges for the company.

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
OrganisationGilead Sciences
Headquarters333 Lakeside Drive, Foster City, CA, United States, 94404
IndustryDrug Manufacturers - General
CEOMr. Daniel Patrick O'Day
E-voting on sharesClick here to vote

Key Management of Gilead Sciences

Name

Title

Dr. Dietmar P. Berger M.D., Ph.D.

Chief Medical Officer

Dr. Flavius Martin M.D.

Executive Vice President of Research

Mr. Daniel Patrick O'Day

Chairman & CEO

Mr. Andrew D. Dickinson

Executive VP & CFO

Ms. Jacquie Ross C.F.A.

Senior Vice President of Treasury & Investor Relations

Ms. Keeley M. Cain Wettan

Executive VP, General Counsel of Legal & Compliance and Secretary

Ms. Jyoti K. Mehra

Executive Vice President of Human Resources

Dr. Linda Slanec Higgins Ph.D.

Senior Vice President of Research, Innovation & Portfolio

Ms. Johanna Mercier

Chief Commercial & Corporate Affairs Officer

Ms. Erin E. Burkhart

Senior VP, Controller & Chief Accounting Officer

FAQs

What is Gilead Sciences share price today?

Gilead Sciences share price today is $145.65 as on at the close of the market. Gilead Sciences share today touched a day high of $147.68 and a low of $145.00.

What is the 52 week high and 52 week low for Gilead Sciences share?

Gilead Sciences share touched a 52 week high of $157.29 on and a 52 week low of $108.46 on . Gilead Sciences stock price today i.e. is closed at $145.65,which is 7.40% down from its 52 week high and 34.29% up from its 52 week low.

What is Gilead Sciences's market capitalisation today?

Gilead Sciences market capitalisation is $0.19T as on .

How to invest in Gilead Sciences Stock (GILD) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Gilead Sciences on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Gilead Sciences Shares that will get you 0.0103 shares as per Gilead Sciences share price of $145.65 per share as on September 10, 2026 at 8:46 am IST.

What is the minimum amount required to buy Gilead Sciences Stock (GILD) from India?

Indian investors can start investing in Gilead Sciences (GILD) shares with as little as ₹95.105 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹951.05 in Gilead Sciences stock (as per the Rupee-Dollar exchange rate as on ). Based on Gilead Sciences share’s latest price of $145.65 as on September 10, 2026 at 8:46 am IST, you will get 0.0687 shares of Gilead Sciences. Learn more about fractional shares .

What are the returns that Gilead Sciences has given to Indian investors in the last 5 years?

Gilead Sciences stock has given 107.68% share price returns and 28.48% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?